| Hypertensive disease
Inderal LA vs Qbrelis
Side-by-side clinical, coverage, and cost comparison for hypertensive disease.Deep comparison between: Inderal vs Qbrelis with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsQbrelis has a higher rate of injection site reactions vs Inderal based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Qbrelis but not Inderal, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Inderal
Qbrelis
At A Glance
Oral
Once daily
Nonselective beta-blocker
Oral
Once daily
ACE inhibitor
Indications
- Hypertensive disease
- Coronary Arteriosclerosis
- Migraine Disorders
- Idiopathic hypertrophic subaortic stenosis
- Hypertensive disease
- Heart Failure, Systolic
- Acute myocardial infarction
Dosing
Hypertensive disease Initial 80 mg once daily; may increase to 120 mg or higher; usual maintenance 120-160 mg once daily; up to 640 mg may be required.
Coronary Arteriosclerosis Start 80 mg once daily; increase at 3-7 day intervals; average optimal dose 160 mg once daily; maximum established dose 320 mg once daily.
Migraine Disorders Initial 80 mg once daily; usual effective range 160-240 mg once daily; discontinue if no response within 4-6 weeks at maximal dose.
Idiopathic hypertrophic subaortic stenosis Usual dosage 80-160 mg once daily.
Hypertensive disease Adults: initial 10 mg once daily (5 mg once daily if on diuretics), titrate to 20-40 mg once daily; pediatric patients >=6 years with GFR >30 mL/min/1.73m2: initial 0.07 mg/kg (up to 5 mg) once daily, maximum 0.61 mg/kg (up to 40 mg) once daily, oral.
Heart Failure, Systolic Initial 5 mg once daily (2.5 mg once daily if hyponatremia present) with diuretics and digitalis; increase as tolerated to 40 mg once daily, oral.
Acute myocardial infarction 5 mg within 24 hours of onset, then 5 mg at 24 hours, then 10 mg once daily for at least 6 weeks; initiate at 2.5 mg once daily if systolic BP <=120 mmHg, oral.
Contraindications
- Cardiogenic shock
- Sinus bradycardia and greater than first-degree block
- Bronchial asthma
- Known hypersensitivity to propranolol hydrochloride
- History of angioedema or hypersensitivity related to previous ACE inhibitor treatment
- Hereditary or idiopathic angioedema
- Co-administration of aliskiren in patients with diabetes
- Combination with a neprilysin inhibitor (e.g., sacubitril); do not administer within 36 hours of switching to or from sacubitril/valsartan
Adverse Reactions
Cardiovascular Bradycardia, congestive heart failure, intensification of AV block, hypotension, paresthesia of hands, thrombocytopenic purpura, arterial insufficiency (Raynaud type)
Central Nervous System Light-headedness, mental depression, insomnia, lassitude, weakness, fatigue, catatonia, visual disturbances, hallucinations, vivid dreams, disorientation, short-term memory loss, emotional lability
Gastrointestinal Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis
Allergic Hypersensitivity reactions including anaphylactic/anaphylactoid reactions, pharyngitis, agranulocytosis, erythematous rash, fever with aching and sore throat, laryngospasm, respiratory distress
Respiratory Bronchospasm
Hematologic Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura
Autoimmune Systemic lupus erythematosus
Skin and Mucous Membranes Stevens-Johnson Syndrome, toxic epidermal necrolysis, dry eyes, exfoliative dermatitis, erythema multiforme, urticaria, alopecia, SLE-like reactions, psoriasisiform rashes
Genitourinary Male impotence, Peyronie's disease
Most common (>=2%) Hypertension: headache, dizziness, cough; Heart Failure: hypotension, chest pain; Acute MI: hypotension.
Serious Bone marrow depression, hemolytic anemia, leukopenia/neutropenia, thrombocytopenia, toxic epidermal necrolysis, Stevens-Johnson syndrome, pancreatitis, hyperkalemia, renal dysfunction.
Postmarketing Hyponatremia, hypoglycemia in diabetic patients, mood alterations, mental confusion, hallucinations, psoriasis.
Pharmacology
Propranolol is a nonselective beta-adrenergic receptor-blocking agent that competitively blocks beta-receptor-stimulating agents, reducing chronotropic, inotropic, and vasodilator responses to beta-adrenergic stimulation; at doses greater than required for beta blockade, it also exerts a quinidine-like membrane action affecting the cardiac action potential.
ACE inhibitor; lisinopril inhibits angiotensin-converting enzyme, reducing conversion of angiotensin I to angiotensin II, thereby decreasing vasopressor activity and aldosterone secretion to lower blood pressure in hypertension, heart failure, and post-myocardial infarction.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Inderal
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (5/12)
Qbrelis
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Inderal
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Qbrelis
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Inderal
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Qbrelis
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Inderal.
No savings programs available for Qbrelis.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
InderalView full Inderal profile
QbrelisView full Qbrelis profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.